Omalizumab for the treatment of severe allergic asthma in children: A tale of two
Abstract Omalizumab is a monoclonal antibody which targets immunoglobulin E. It is approved as an add‐on therapy for children with severe allergic asthma. Assessment of endotype and phenotype is necessary in order to correctly identify those patients who are most likely to respond to omalizumab. Chi...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-08-01
|
| Series: | Clinical Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ccr3.6255 |